Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline
This rodent study (2022) assessed the effects of LSD administration on anxiety-like behaviour, on the cortical dendritic spines and on the activity of serotonin neurons in mice exposed to chronic restraint stress. LSD dose of 30 µg/kg (daily for 7 days) prevented the stress-induced anxiety-like behaviour and the stress-induced decrease of cortical spine density. LSD acutely decreased the firing activity of serotonin neurons, yet repeated LSD increased their basal firing rate and restored the low serotonin firing induced by stress. Overall, repeated LSD prevents the exacerbation of anxiety-like behaviour following chronic stress exposure, but has no behavioural effects in non-stressed mice.
Authors
- Danilo De Gregorio
- Gabriella Gobbi
Published
Abstract
Lysergic acid diethylamide (LSD) is a serotonergic psychedelic compound receiving increasing interest due to putative anxiolytic and antidepressant properties. However, the potential neurobiological mechanisms mediating these effects remain elusive. Employing in vivo electrophysiology, microionthophoresis, behavioural paradigms and morphology assays, we assessed the impact of acute and chronic LSD administration on anxiety-like behaviour, on the cortical dendritic spines and on the activity of serotonin (5-HT) neurons originating in the dorsal raphe nucleus (DRN) in male mice exposed to chronic restraint stress. We found that while the acute intraperitoneal (i.p.) administration of LSD (5, 15 and 30 and 60 μg/kg) did not produce any anxiolytic or antidepressant effects in non-stressed mice, the dose of 30 µg/kg (daily for 7 days) prevented the stress-induced anxiety-like behaviour and the stress-induced decrease of cortical spine density. Interestingly, while LSD acutely decreased the firing activity of 5-HT neurons, repeated LSD increased their basal firing rate and restored the low 5-HT firing induced by stress. This effect was accompanied by a decreased inhibitory response of 5-HT neurons to microiontophoretic applications of the 5-HT1A agonist 8-OH-DPAT (8-hydroxy-N,N-dipropyl-2-aminotetralin). In conclusion, repeated LSD prevents the exacerbation of anxiety-like behaviour following chronic stress exposure, but has no behavioural effects in non-stressed mice. These effects are paralleled by increased cortical spinogenesis and an enhancement of 5-HT neurotransmission which might be due to 5-HT1A receptors desensitization. Increased cortical spine density and enhancement of serotonergic neurotransmission may thus represent a candidate mechanism which mediates the therapeutic effects of serotonergic psychedelics on stress-induced anxiety.
Research Summary of 'Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline'
Introduction
Psychedelic compounds have re-emerged as candidate psychiatric therapeutics, with lysergic acid diethylamide (LSD) drawing attention for putative anxiolytic and antidepressant properties. Earlier clinical and preclinical work suggests LSD acts at serotonin (5-HT) receptors, producing prosocial and mood effects in humans and modulating serotonergic and dopaminergic systems in animals; however, the precise neurobiological mechanisms that might underlie therapeutic actions remain unclear. Prior studies by the group showed dose-dependent effects of LSD on 5-HT and dopamine systems, and a 7-day low-dose regimen was previously linked to increased sociability and mPFC mTORC1 activation, motivating further mechanistic inquiry into stress-related outcomes. De Gregorio and colleagues set out to test whether acute or repeated low-dose LSD alters anxiety- and depressive-like behaviours, cortical dendritic spine density, and dorsal raphe nucleus (DRN) 5-HT neuronal activity in male mice exposed to chronic restraint stress. The study tested multiple acute doses (5, 15, 30 and 60 µg/kg, i.p.) for immediate behavioural effects, and evaluated a 7-day repeated regimen (5, 15 and 30 µg/kg/day, administered during the last week of a 15-day chronic restraint stress paradigm) for protective effects on stress-induced behavioural and neurobiological alterations. The work aimed to link behavioural outcomes to synaptogenesis and electrophysiological changes in 5-HT neurotransmission, with particular attention to potential desensitisation of 5-HT1A autoreceptors.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
De Gregorio, D., Inserra, A., Enns, J. P., Markopoulos, A., Pileggi, M., El Rahimy, Y., Lopez-Canul, M., Comai, S., & Gobbi, G. (2022). Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline. Neuropsychopharmacology, 47(6), 1188-1198. https://doi.org/10.1038/s41386-022-01301-9
References (20)
Papers cited by this study that are also in Blossom
Inserra, A., De Gregorio, D., Gobbi, G. · Pharmacological Reviews (2021)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Dolder, P. C., Schmid, Y., Müller, F. et al. · Neuropsychopharmacology (2016)
Mueller, F., Lenz, C., Dolder, P. C. et al. · Translational Psychiatry (2017)
Schmid, Y., Liechti, M. E. · Psychopharmacology (2017)
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M. et al. · Psychological Medicine (2016)
Kirchner, K. · Journal of Psychopharmacology (2014)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
De Gregorio, D., Posa, L., Ochoa-Sanchez, R. et al. · Pharmacological Research (2016)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
Show all 20 referencesShow fewer
Markopoulos, A., Inserra, A., De Gregorio, D. et al. · Frontiers in Pharmacology (2022)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Therapeutic Advances in Psychopharmacology (2016)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Buchborn, T., Schröder, H., Höllt, V. et al. · Journal of Psychopharmacology (2014)
Grossman, L., Utterback, E., Stewart, A. et al. · Behavioural Brain Research (2010)
Cameron, L. P., Benson, C. J., Defelice, B. C. et al. · ACS Chemical Neuroscience (2019)
Jefsen, O., Højgaard, K., Christiansen, S. L. et al. · Acta Neuropsychiatrica (2019)
Hesselgrave, N., Troppoli, T. A., Wulff, A. B. et al. · PNAS (2021)
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · ACS Pharmacology and Translational Science (2020)
Galvão-Coelho, N. L., de Almeida, R. N., de Menezes Galvão, A. C. et al. · Frontiers in Psychology (2019)
Cited By (8)
Papers in Blossom that reference this study
Agnorelli, C., Spriggs, M. J., Godfrey, K. et al. · Preprints (2024)
Peill, J. M., Marguilho, M., Erritzoe, D. et al. · Journal of Psychopharmacology (2024)
Heifets, B. D., Olson, D. E. · Neuropsychopharmacology (2023)
Tiwari, P., Sayali, C., Doss, M. K. et al. · Psychedelic Medicine (2023)
Lewis, V., Bonniwell, E. M., Lanham, J. K. et al. · Cell Reports (2023)
Ornelas, I. M., Cini, F. A., Wießner, I. et al. · Experimental Neurology (2022)
Calder, A. E., Hasler, G. · Neuropsychopharmacology (2022)
van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.